PPV without ILM peeling favourable for ODP

Article

Pars plana vitrectomy, endolaser photocoagulation and C3F8 gas tamponade without internal limiting membrane (ILM) peeling have been found to be potentially favourable in the treatment of optic disc pit (ODP) maculopathy, according to data published in Eye.

Pars plana vitrectomy, endolaser photocoagulation and C3F8 gas tamponade without internal limiting membrane (ILM) peeling have been found to be potentially favourable in the treatment of optic disc pit (ODP) maculopathy, according to data published in Eye.

Dr R. Avci et al. (Retina Eye Hospital, Bursa, Turkey) examined 13 eyes from 12 patients undergoing surgery to treat serous macular detatchment and/or macular retinoschisis secondary to congenital ODP. All patients included in the study were treated with PPV, posterior hyaloid removal, endolaser photocoagulation on the temporal margin of the optic disc and 12% C3F8 gas tamponade.

The team used optical coherence tomography (OCT) to analyse the anatomic success and functional outcome of surgery and they measured the patients’ best-corrected visual acuity (BCVA) as well. The majority of the study group experienced an improvement in BCVA of 2 lines or more and 12 eyes experienced complete reabsorption or subretinal and intraretinal fluid.

These results indicated that PPV, C3F8 gas tamponade and endolaser to the optic disc margin without ILM peeling could be a beneficial surgical option for patients suffering with ODP maculopathy and earlier surgical intervention leads to better visual improvements.

For further information please view the abstract here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.